- RecruitingPHASE3
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
This study compares a new medication, Bomedemstat, with a standard treatment, Hydroxyurea, for people with Essential Thrombocythemia (ET). It wants to see if Bomedemstat works better at controlling ET for those new to treatment.
For: Essential ThrombocythemiaUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
This study is for people already taking a medicine called bomedemstat for certain blood cancers like thrombocythemia or myelofibrosis. It aims to gather more information over a longer time about how safe and effective bomedemstat is for those who are already benefiting from it.
For: Thrombocythemia, Essential · Primary Myelofibrosis · MyelofibrosisUnited States · Australia · Hong Kong - RecruitingPHASE3
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
This study looks at a new drug, bomedemstat, for essential thrombocythemia (ET). It compares bomedemstat to standard treatments for people whose current medicine, hydroxyurea, isn't working well or causes too many side effects. We want to see if bomedemstat is safer and works better.
For: Essential ThrombocythemiaUnited States · Argentina · Australia